Thursday, 28 June 2012

Biopharmaceutical Company-Herborium Group Reports-Phase 2 Clinical Trial-Mycobacteria

Med Centro Becomes First SuccessEHS Client to Go Live in Puerto Rico

BIRMINGHAM, Ala., June 27, 2012 /PRNewswire/ -- On June 5, 2012, Med Centro became the first SuccessEHS client in Puerto Rico to go live with the SuccessEHS solution, expanding the vendor's existing coverage in 48 states and the Virgin Islands.The go-live on June 5 took place... read more..


Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease

MONMOUTH JUNCTION, N.J., June 27, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in... read more..


Herborium Group Reports Record 6 Month Revenues

FORT LEE, N.J., June 27, 2012 /PRNewswire/ -- Herborium Group, Inc., ( HBRM) www.herborium.com, a Botanical Therapeutics® Company announces today that its revenues   from AcnEase®, all botanical, proprietary acne treatment, grew over 25 percent in  the first ... read more..

No comments:

Post a comment